Document is current
Any future updates will be listed below
-
Authors
Brantley, Kristen D.
Kirkner, Gregory J.
Hughes, Melissa E.
Varella, Leticia
Suggs, Georgia
Cunningham, Olivia M.
Ravikumar, Sanjana
Snow, Craig
Tolaney, Sara M.
Sammons, Sarah
Partridge, Ann H.
Lin, Nancy U.
-
Funding
Funding for this research was provided by:
National Cancer Institute (T32 CA009001)
Susan G. Komen
Breast Cancer Research Foundation
Pan-Mass Challenge
NCCN/Pfizer Independent Grants for Learning & Change
Elaine and Eduardo Saverin Foundation
- License Information
-
More Information
Article History
Received: 30 May 2025
Accepted: 20 August 2025
First Online: 29 August 2025
Competing interests
: S.M.T. reports consulting or advisory role for Novartis, Pfizer/SeaGen, Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Bristol Myers Squibb/Systimmune, Daiichi Sankyo, Gilead, Blueprint Medicines, Reveal Genomics, Sumitovant Biopharma, Artios Pharma, Menarini/Stemline, Aadi Bio, Bayer, Jazz Pharmaceuticals, Natera, Tango Therapeutics, eFFECTOR, Hengrui USA, Cullinan Oncology, Circle Pharma, Arvinas, BioNTech, Launch Therapeutics, Zuellig Pharma, Johnson&Johnson/Ambrx, Bicycle Therapeutics, BeiGene Therapeutics, Mersana, Summitt Therapeutics, Avenzo Therapeutics, Aktis Oncology, Celcuity, Boehringer Ingelheim, Samsung Bioepis, Olema Pharmaceuticals; research funding from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, AstraZeneca, NanoString Technologies, Gilead, SeaGen, OncoPep, Daiichi Sankyo, Menarini/Stemline, Jazz Pharmaceuticals; travel support from Lilly, Gilead, Jazz Pharmaceuticals, Pfizer, Arvinas, Roche. S.S. reports institutional research funding from Daichi Sankyo, Relay Therapeutics, SEAGEN and Sermonix; and consulting/advisory fees from Astra Zeneca, Daichi Sankyo, Gilead, Eli Lilly, Incyclix, Pfizer, Sermonix, SEAGEN, and Novartis. N.U.L. reports institutional research support from Genentech, Pfizer, Merck, Seattle Genetics, Zion Pharmaceuticals, Olema Pharmaceuticals, AstraZeneca; consulting honoraria from Seattle Genetics, Daichii-Sankyo, AstraZeneca, Olema Pharmaceuticals, Janssen, Blueprint Medicines, Stemline/Menarini, Artera Inc., Eisai, Shorla Oncology; royalties from Up to date (book); and travel support from Olema, AstraZeneca, DSI. The remaining authors report no competing interests.
